Earnings per Share (EPS) of $0.01 was reported, falling below the estimated$0.08.Record quarterly service revenue of $14.9 million in Q2 2026, marking an 11$15 million.Oncology services segment reported a profit of $7.8 million, with a margin of 52%, indicating strong performance.Champions Oncology, Inc. (NASDAQ:CSBR) is a key player in the field of translational oncology research. The company specializes in providing comprehensive research and development solutions to biopha ...